---
document_datetime: 2025-12-02 05:31:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ilaris.html
document_name: ilaris.html
version: success
processing_time: 0.1530096
conversion_datetime: 2025-12-25 06:42:50.789345
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ilaris

[RSS](/en/individual-human-medicine.xml/66419)

##### Authorised

This medicine is authorised for use in the European Union

canakinumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ilaris](#news-on)
- [More information on Ilaris](#more-information-on-ilaris-696)
- [More information on Ilaris](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ilaris. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ilaris.

For practical information about using Ilaris, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Ilaris and what is it used for?

Ilaris is a medicine for treating the following inflammatory conditions:

- 4 types of periodic fever syndromes (diseases marked by recurring inflammation and fever) in adults and children aged 2 and above:
    - cryopyrin-associated periodic syndromes (CAPS);
    - tumour necrosis factor receptor associated periodic syndrome (TRAPS);
    - hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD);
    - familial mediterranean fever (FMF);
- Still's disease, a rare disease causing inflammation of joints as well as rash and fever (in adults and children aged 2 and above);
- Gouty arthritis, painful inflammation of the joints caused by deposit of urate crystals (in adults).

Ilaris contains the active substance canakinumab.

## How is Ilaris used?

Ilaris is given as a single injection under the skin every 8 weeks for CAPs and every 4 weeks for the other periodic fever syndromes (TRAPS, HIDS/MKD and FMF) and Still's disease. In patients with gouty arthritis, a single injection is given on-demand to treat gouty arthritis attacks.

Injections are usually given in the upper thigh, upper arm, abdomen or buttocks. After proper training, patients or their caregivers may inject Ilaris themselves if the doctor deems it appropriate (for gouty arthritis the medicine should always be given by a healthcare professional). For information on doses and dose adjustments, see the summary of product characteristics (also part of the EPAR).

Ilaris can only be obtained with a prescription.

## How does Ilaris work?

The active substance in Ilaris, canakinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a messenger molecule or 'cytokine' in the body called interleukin?1 beta. This messenger is involved in causing inflammation and is found in high levels in patients with periodic fever syndromes, Still's disease and gouty arthritis. By attaching to interleukin?1 beta, canakinumab blocks its activity, helping to reduce inflammation thereby relieving the symptoms of the diseases.

## What benefits of Ilaris have been shown in studies?

**Periodic fever syndromes**

Three studies involving 220 adults and children 2 years and older showed that Illaris was effective at reducing relapses of CAPS symptoms after a 24-week treatment period. In one of the studies, none of the patients with CAPS who received Ilaris during the 24-week treatment period had a relapse, compared with 81% of patients who received placebo (a dummy treatment). In the two other CAPS studies, which did not compare Ilaris with any other treatment, 85% of patients on Ilaris had no relapses at all. The proportion of patients with no relapse was lower (around 57%) for children aged 2 to 4 years.

A fourth study in 181 patients with other periodic fever syndromes found that Ilaris was more effective than placebo in achieving a response (symptoms resolved with no new flare ups). The response rates with Ilaris and placebo were 46% and 8%, respectively in patients with TRAPS, 35% and 6% in patients with HIDS/MKD, and 61% and 6% in patients with FMF.

**Still's disease**

A study in 84 patients with childhood Still's disease (also known as systemic juvenile idiopathic arthritis, SJIA) found that Ilaris was more effective than placebo at reducing symptoms of arthritis: around 84% of patients who received Ilaris achieved the required reduction in symptoms, compared with about 10% of patients who received placebo. In a second study in childhood Still's disease (177 patients), the risk of experiencing a disease flare was reduced by 64% with Ilaris, compared with placebo. Ilaris treatment also allowed patients to reduce the amount of steroids they take to control inflammation.

Because of the similarities between childhood Still's disease and the adult form (adult-onset Still's disease, AOSD), Ilaris is expected to have similar benefits in adults.

**Gouty arthritis**

Two studies involving 454 patients with gouty arthritis showed that Ilaris was more effective than another anti-inflammatory medicine triamcinolone acetonide at reducing pain. In patients taking Ilaris, after 3 days, the pain level was reduced from 74 to 25 (on a standard rating scale from 0 to 100), whereas in patients taking the comparator the pain level was reduced from 74 to 35. The risk of developing a new gouty arthritis attack was also reduced with Ilaris (17% with Ilaris versus 37% with triamcinolone acetonide).

## What are the risks associated with Ilaris?

Serious infections have been observed in patients taking Ilaris. The most common infections were of the nose and throat. Some infections were unusual or opportunistic infections due to reduced white blood cell levels. For the full list of all side effects reported with Ilaris, see the package leaflet.

Ilaris must not be used in patients with active or severe infection. For the full list of restrictions, see the package leaflet.

## Why is Ilaris approved?

Studies have shown that Ilaris is effective at reducing symptoms or relapses in patients with periodic fever syndromes, Still's disease and gouty arthritis. The main risk with this medicine is infection, mostly affecting the nose and throat. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits seen with Ilaris outweigh its risks and recommended that it be authorised in the EU.

Ilaris was originally authorised under 'exceptional circumstances', because, for scientific reasons, limited information was available at the time of approval. As the company had supplied the additional information requested, the 'exceptional circumstances' ended on 22 March 2017.

## What measures are being taken to ensure the safe and effective use of Ilaris?

The company that markets Ilaris will provide doctors who will use Ilaris with educational material containing the prescribing information, the patient reminder card and information for doctors containing important safety information about Ilaris, including precautions to be taken when using the medicine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ilaris have also been included in the summary of product characteristics and the package leaflet.

## Other information about Ilaris

The European Commission granted a marketing authorisation valid throughout the European Union for Ilaris on 23 October 2009.

For more information about treatment with Ilaris, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ilaris : EPAR - Summary for the public

English (EN) (85.94 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 17/05/2017

[View](/en/documents/overview/ilaris-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-380)

български (BG) (115.5 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/bg/documents/overview/ilaris-epar-summary-public_bg.pdf)

español (ES) (118.28 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/es/documents/overview/ilaris-epar-summary-public_es.pdf)

čeština (CS) (114.46 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/cs/documents/overview/ilaris-epar-summary-public_cs.pdf)

dansk (DA) (83.9 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/da/documents/overview/ilaris-epar-summary-public_da.pdf)

Deutsch (DE) (117.5 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/de/documents/overview/ilaris-epar-summary-public_de.pdf)

eesti keel (ET) (94 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/et/documents/overview/ilaris-epar-summary-public_et.pdf)

ελληνικά (EL) (115.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/el/documents/overview/ilaris-epar-summary-public_el.pdf)

français (FR) (86.81 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/fr/documents/overview/ilaris-epar-summary-public_fr.pdf)

hrvatski (HR) (103.54 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/hr/documents/overview/ilaris-epar-summary-public_hr.pdf)

italiano (IT) (84.96 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/it/documents/overview/ilaris-epar-summary-public_it.pdf)

latviešu valoda (LV) (109.56 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/lv/documents/overview/ilaris-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (110.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/lt/documents/overview/ilaris-epar-summary-public_lt.pdf)

magyar (HU) (108.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/hu/documents/overview/ilaris-epar-summary-public_hu.pdf)

Malti (MT) (114.66 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/mt/documents/overview/ilaris-epar-summary-public_mt.pdf)

Nederlands (NL) (85.68 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/nl/documents/overview/ilaris-epar-summary-public_nl.pdf)

polski (PL) (119.74 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/pl/documents/overview/ilaris-epar-summary-public_pl.pdf)

português (PT) (114.49 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/pt/documents/overview/ilaris-epar-summary-public_pt.pdf)

română (RO) (116.59 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/ro/documents/overview/ilaris-epar-summary-public_ro.pdf)

slovenčina (SK) (113.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/sk/documents/overview/ilaris-epar-summary-public_sk.pdf)

slovenščina (SL) (108.72 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/sl/documents/overview/ilaris-epar-summary-public_sl.pdf)

Suomi (FI) (83.48 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/fi/documents/overview/ilaris-epar-summary-public_fi.pdf)

svenska (SV) (84.37 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

17/05/2017

[View](/sv/documents/overview/ilaris-epar-summary-public_sv.pdf)

Ilaris : EPAR - Risk management plan

English (EN) (2.93 MB - PDF)

**First published:** 11/12/2024

[View](/en/documents/rmp/ilaris-epar-risk-management-plan_en.pdf)

## Product information

Ilaris : EPAR - Product Information

English (EN) (1.26 MB - PDF)

**First published:** 12/11/2009

**Last updated:** 05/02/2025

[View](/en/documents/product-information/ilaris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-573)

български (BG) (1.36 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/bg/documents/product-information/ilaris-epar-product-information_bg.pdf)

español (ES) (1.32 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/es/documents/product-information/ilaris-epar-product-information_es.pdf)

čeština (CS) (1.29 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/cs/documents/product-information/ilaris-epar-product-information_cs.pdf)

dansk (DA) (1.33 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/da/documents/product-information/ilaris-epar-product-information_da.pdf)

Deutsch (DE) (1.3 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/de/documents/product-information/ilaris-epar-product-information_de.pdf)

eesti keel (ET) (1.28 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/et/documents/product-information/ilaris-epar-product-information_et.pdf)

ελληνικά (EL) (1.43 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/el/documents/product-information/ilaris-epar-product-information_el.pdf)

français (FR) (1.41 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/fr/documents/product-information/ilaris-epar-product-information_fr.pdf)

hrvatski (HR) (1.32 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/hr/documents/product-information/ilaris-epar-product-information_hr.pdf)

íslenska (IS) (1.31 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/is/documents/product-information/ilaris-epar-product-information_is.pdf)

italiano (IT) (1.37 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/it/documents/product-information/ilaris-epar-product-information_it.pdf)

latviešu valoda (LV) (1.38 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/lv/documents/product-information/ilaris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.38 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/lt/documents/product-information/ilaris-epar-product-information_lt.pdf)

magyar (HU) (1.46 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/hu/documents/product-information/ilaris-epar-product-information_hu.pdf)

Malti (MT) (1.48 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/mt/documents/product-information/ilaris-epar-product-information_mt.pdf)

Nederlands (NL) (1.32 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/nl/documents/product-information/ilaris-epar-product-information_nl.pdf)

norsk (NO) (1.29 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/no/documents/product-information/ilaris-epar-product-information_no.pdf)

polski (PL) (1.42 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/pl/documents/product-information/ilaris-epar-product-information_pl.pdf)

português (PT) (1.32 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/pt/documents/product-information/ilaris-epar-product-information_pt.pdf)

română (RO) (1.49 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/ro/documents/product-information/ilaris-epar-product-information_ro.pdf)

slovenčina (SK) (1.46 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/sk/documents/product-information/ilaris-epar-product-information_sk.pdf)

slovenščina (SL) (1.4 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/sl/documents/product-information/ilaris-epar-product-information_sl.pdf)

Suomi (FI) (1.33 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/fi/documents/product-information/ilaris-epar-product-information_fi.pdf)

svenska (SV) (1.29 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

05/02/2025

[View](/sv/documents/product-information/ilaris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246279 04/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ilaris : EPAR - All Authorised presentations

English (EN) (48.49 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 11/12/2024

[View](/en/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-879)

български (BG) (65.69 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/bg/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_bg.pdf)

español (ES) (57 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/es/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/cs/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.18 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/da/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/de/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/et/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.99 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/el/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_el.pdf)

français (FR) (58.35 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/fr/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (59.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/hr/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (58.85 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/is/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.86 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/it/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.07 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/lv/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.23 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/lt/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/hu/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.54 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/mt/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (56.45 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/nl/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.28 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/no/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.54 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/pl/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.36 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/pt/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.05 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/ro/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.02 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/sk/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.52 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/sl/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (54.68 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/fi/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (57.75 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

11/12/2024

[View](/sv/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_sv.pdf)

Ilaris : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (32.38 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-610)

български (BG) (116.95 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/bg/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (32.86 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/es/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (119.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/cs/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (32.68 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/da/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (33.04 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/de/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (32.6 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/et/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (111.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/el/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (31.16 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fr/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (32.56 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/it/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (119.26 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lv/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (116.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lt/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (114.46 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/hu/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (119.4 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/mt/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (75.03 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/nl/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (120.41 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pl/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (32.86 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pt/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (116.08 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/ro/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (117.88 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sk/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (110.03 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sl/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (36.76 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fi/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (32.63 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sv/documents/conditions-member-states/ilaris-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Ilaris Active substance Canakinumab International non-proprietary name (INN) or common name canakinumab Therapeutic area (MeSH)

- Cryopyrin-Associated Periodic Syndromes
- Arthritis, Juvenile Rheumatoid
- Arthritis, Gouty

Anatomical therapeutic chemical (ATC) code L04AC08

### Pharmacotherapeutic group

Interleukin inhibitors

### Therapeutic indication

**Periodic fever syndromes**

Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

***Cryopyrin-associated periodic syndromes***

Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:

- Muckle-Wells syndrome (MWS),
- Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),
- Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.

***Tumour necrosis factor receptor associated periodic syndrome (TRAPS)***

Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).

***Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)***

Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).

***Familial Mediterranean fever (FMF)***

Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.

Ilaris is also indicated for the treatment of:

**Still's disease**

Ilaris is indicated for the treatment of active Still's disease including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.

**Gouty arthritis**

Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

## Authorisation details

EMA product number EMEA/H/C/001109 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 23/10/2009 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ilaris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (121.66 KB - PDF)

**First published:** 05/02/2025

[View](/en/documents/procedural-steps-after/ilaris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ilaris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (307.52 KB - PDF)

**First published:** 27/04/2010

**Last updated:** 05/02/2025

[View](/en/documents/procedural-steps-after/ilaris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ilaris-PAM-0000280285 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2226547

English (EN) (474.83 KB - PDF)

**First published:** 13/10/2025

[View](/en/documents/variation-report/ilaris-pam-0000280285-epar-assessment-report_en.pdf)

Ilaris-H-C-001109-P46-059 : EPAR - Assessment report

Adopted

Reference Number: EMA/112036/2024

English (EN) (351.12 KB - PDF)

**First published:** 13/03/2024

[View](/en/documents/variation-report/ilaris-h-c-001109-p46-059-epar-assessment-report_en.pdf)

Ilaris-H-C-001109-P46-058 : EPAR - Assessment Report

Adopted

Reference Number: EMA/760908/2022

English (EN) (835.3 KB - PDF)

**First published:** 14/09/2022

[View](/en/documents/variation-report/ilaris-h-c-001109-p46-058-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-P46-053 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/269473/2019

English (EN) (522.07 KB - PDF)

**First published:** 16/05/2019

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-053-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-P46-052 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/269480/2019

English (EN) (503.02 KB - PDF)

**First published:** 16/05/2019

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-052-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-X-0045-G : EPAR - Assessment Report - Variation

English (EN) (1.56 MB - PDF)

**First published:** 02/03/2017

**Last updated:** 02/03/2017

[View](/en/documents/variation-report/ilaris-h-c-1109-x-0045-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ilaris

Adopted

Reference Number: EMA/CHMP/827091/2016

English (EN) (80.1 KB - PDF)

**First published:** 16/12/2016

**Last updated:** 16/12/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-3)

Ilaris-H-C-1109-P46-049 : EPAR - Assessment Report

English (EN) (187.83 KB - PDF)

**First published:** 07/10/2016

**Last updated:** 07/10/2016

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-049-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-P46-048 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/577659/2016

English (EN) (160.88 KB - PDF)

**First published:** 13/09/2016

**Last updated:** 13/09/2016

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-048-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-II-0043 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/493970/2016

English (EN) (2.98 MB - PDF)

**First published:** 08/09/2016

**Last updated:** 08/09/2016

[View](/en/documents/variation-report/ilaris-h-c-1109-ii-0043-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ilaris

Adopted

Reference Number: EMA/CHMP/421628/2016

English (EN) (76 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-1)

Ilaris : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/850660/2015

English (EN) (69.12 KB - PDF)

**First published:** 08/01/2016

**Last updated:** 08/01/2016

[View](/en/documents/pip-compliance/ilaris-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Ilaris-H-C-1109-P46-0043 : EPAR - Assessment Report

Adopted

Reference Number: EMA/554401/2015

English (EN) (303.74 KB - PDF)

**First published:** 05/10/2015

**Last updated:** 05/10/2015

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-0043-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-P46-0040 : EPAR - Assessment Report

Adopted

Reference Number: EMA/334385/2015

English (EN) (220.13 KB - PDF)

**First published:** 20/05/2015

**Last updated:** 20/05/2015

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-0040-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-P46-0041 : EPAR - Assessment Report

Adopted

Reference Number: EMA/334374/2015

English (EN) (434.31 KB - PDF)

**First published:** 20/05/2015

**Last updated:** 20/05/2015

[View](/en/documents/variation-report/ilaris-h-c-1109-p46-0041-epar-assessment-report_en.pdf)

Ilaris-H-C-1109-PSUV-0032 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/602161/2014

English (EN) (61.39 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/ilaris-h-c-1109-psuv-0032-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Ilaris-H-C-1109-II-0026 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/427081/2013

English (EN) (4.68 MB - PDF)

**First published:** 11/10/2013

**Last updated:** 11/10/2013

[View](/en/documents/variation-report/ilaris-h-c-1109-ii-0026-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ilaris

Adopted

Reference Number: EMA/CHMP/433406/2013

English (EN) (76.12 KB - PDF)

**First published:** 26/07/2013

**Last updated:** 26/07/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-0)

Ilaris-H-C-1109-II-0021 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/748727/2012

English (EN) (3.07 MB - PDF)

**First published:** 02/04/2013

**Last updated:** 02/04/2013

[View](/en/documents/variation-report/ilaris-h-c-1109-ii-0021-epar-assessment-report-variation_en.pdf)

Ilaris-H-C-1109-II-0010 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/1634/2013

English (EN) (5.75 MB - PDF)

**First published:** 02/04/2013

**Last updated:** 02/04/2013

[View](/en/documents/variation-report/ilaris-h-c-1109-ii-0010-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ilaris

Reference Number: EMA/CHMP/789757/2012

English (EN) (58.75 KB - PDF)

**First published:** 14/12/2012

**Last updated:** 14/12/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ilaris_en.pdf-2)

## Initial marketing authorisation documents

Ilaris : EPAR - Public assessment report

English (EN) (853.49 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/assessment-report/ilaris-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Ilaris

Reference Number: EMEA/CHMP/447829/2009

English (EN) (78.35 KB - PDF)

**First published:** 24/07/2009

**Last updated:** 24/07/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ilaris_en.pdf)

#### News on Ilaris

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022) 11/11/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2016) 16/12/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-january-2013) 18/01/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2012) 14/12/2012

- [Clinical data (variation II/0043)](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC001109II0043)

#### More information on Ilaris

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu307439) on 20 March 2007. Upon request of the marketing-authorisation holder, Ilaris has now been removed from the Community register of orphan medicinal products.

#### More information on Ilaris

- [EMEA-000060-PIP01-07-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip01-07-m03)
- [EMEA-000060-PIP02-08-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip02-08-m06)
- [EMEA-000060-PIP04-14-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip04-14-m01)
- [EMEA-000060-PIP05-14-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip05-14-m01)
- [EMEA-000060-PIP07-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip07-19)
- [EMEA-000060-PIP08-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip08-19)
- [EMEA-000060-PIP09-20 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000060-pip09-20)
- [Ilaris - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/ilaris)
- [Pharmacovigilance In Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents And/Or Methotrexate. A Pediatric Rheumatology International Trials Organisation (PRINTO)/Pediatric Rheumatology European Society (PRES) Registry (Pharmachild JIA registry) - post-authorisation study](https://catalogues.ema.europa.eu/study/49777)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/10/2025

## Share this page

[Back to top](#main-content)